Hansoh Pharma (03692) has announced that its product, HS-20093 (Rezenvaninab vedotin for injection), has been accepted into the priority review and approval process by China's National Medical Products Administration (NMPA) for the treatment of osteosarcoma.

According to the company's announcement dated September 14, 2026, this designation is based on the positive results of the pivotal Phase III trial ARTEMIS-011. The indication covers patients aged 12 years and older with osteosarcoma who have failed at least two prior lines of therapy.

The inclusion in the priority review program is expected to expedite the regulatory review process for this potentially important treatment option in an area of high unmet medical need.